Our Science
(E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC.
Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene if granted.
Bisantrene clinical activity has been evaluated in over 50 human trials with more than 1,500 patients treated, demonstrating both efficacy and a well characterised safety profile.
Reformulated (E,E)-bisantrene – RC220
Racura has developed a novel formulation of (E,E)-bisantrene (RC220) to allow administration via a peripheral vein while maintaining the pharmacokinetics and anticancer activity of the historical formulation.
